Population studies have shown that abnormal #lipidmetabolism and #insulinresistance are significant risk factors for a type of #cancer called #endometrialcarcinoma .
anticancer360.com/how-to-use-mil…
Deepo prover is given weekely as a hormone therapy in the treatment of #EndometrialCarcinoma #gynecology
#EndometrialCarcinoma stage IVB: Distant metastases, including intra-abdominal and/or inguinal lymph nodes.
I'm still liking and re-tweeting this. #lynchsyndrome #bowelcancer #carcinoma #endometrialcarcinoma #linkedcancers #wednesdaythought
ESGO ESHRE ESGE Journal Facts, Views and Vision in ObGyn Pedro T Ramirez Check this 👉🏽 ijgc.bmj.com/content/33/2/2…
@hsumd Aarthi S Jayraj @andrefernandes2 OncoAlert Ane Gerda Z Eriksson MD PhD IJGC Fellows Dr. Fernando Hidalgo , MD FACS Jorge Hoegl. MD René Pareja
Erick Estrada Julio Lau European Network of Young Gynae Oncologists
Can we skip the POLE testing? NO, unless it is a Low-risk #endometrialcarcinoma case! #GYNpath #PathTwitter ~ Now at the #Uscap2023 #Uscap23 by Carlos Parra-Herran MD #shortcourse 👏🏻
All you need to know about Endometrial Cancer whatsthe-trend.com/all-you-need-t…
#endometrialcancer #cancer #stageofendometrialcancer #fallopiantubes #endometrialglands #symptomsofendometrialcancer #diagnosingendometrialcancer #endometrialcarcinoma
🔥🔥🔥Full house when Beryl Manning-Geist, MD presents her work on #fertilitysparing in #endometrialcarcinoma
👩🏽🦳👱🏻♀️🧕🏽➡️🧫➡️🤰🏾🫄🏼
#SGOMtg
MSKCC Team Uterus SGO Eric Rios-Doria, MD
Expression of PTEN Marker in Endometrial Hyperplasia without Atypia: One-year Observational Study jsafog.com/doi/JSAFOG/pdf… #Endometrialcancer #Endometrialcarcinoma #Endometrialhyperplasia #PTEN #JaypeeJournals #JSAFOG #JaideepMalhotra
📢👏🏻🏆Congratulations to Mansoor Mirza and the #RUBYtrial team and to patients who hopefully will can benefit from #immuntherapy 💉🏥🧪 in advanced #endometrialcarcinoma
ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with #endometrialcarcinoma
SoMe4GynOnc Modern Fertility Women in Oncology #GynCancer #obgyntwitter
🔗in original post👇
#Lenvatinib plus #pembrolizumab has been approved by the #FDA for patients with advanced #EndometrialCarcinoma :
i3health.us/news/lenvatini…
@sloan_kettering #EndometrialCancer #oncology #CancerNews
FEB ISSUE: Added Value of SPECT/CT in #SentinelLymphNodes Mapping for #EndometrialCarcinoma . ow.ly/XrnIM
#caseoftheday dedifferentiated endometrial carcinoma. 2 tumours in one!! #gynpath #pathology #endometrialcarcinoma
We are committed to advancing our innovative pipeline forward for areas of significant unmet need. Learn more at: bit.ly/3npZn3X
$CNSP #Oncology #Glioblastoma #Glioblastoma Multiforme #GBM
#EndometrialCarcinoma and #Bisphenol A: A Pilot Case-Control Study by Laura Sarno* in #BJSTR
biomedres.us/fulltexts/BJST…
Follow on blogger :: biomedres01.blogspot.com
Like our pins on :: pinterest.com/biomedres/
Drs. Donal Brennan and J. Prat kicking off #IGCS2019 “Clinical Application of Molecular #Genetics to the Classification and Staging of #EndometrialCarcinoma ” So great to take part in this session with Jenny Mueller MD IGCS IJGC Nadeem R. Abu-Rustum
Mansoor Mirza presenting practice changing Ruby trial results at #SGOmtg
✅Dostarlimab +Carbo/Taxol in advanced&recurrent #EndometrialCancer
✅2yr PFS dMMR 61.4% HR0.28(95%CI 0.16-0.49)
✅2yr OS dMMR 83.3% HR0.30(95%CI 0.13-0.7)
✅dMMR ORR 77.6% w durable response & well-tolerated
Xenetic Biosciences is a biopharmaceutical company focused on advancing proprietary technology platforms across multiple high-value cancer indications. Learn more about us here: bit.ly/3xixJIx
$XBIO #Oncology #SolidTumors #PancreaticCancer #CARTcells
I made a bet. I lost. But it still paid off. LEAD FROM BEHIND Rob McElhenney Jonathan LaPook, M.D @NYULangone Rob McElhenney
Catching up on #Immunotherapy for #endometrialcarcinoma at ESMO, thinking of #TeamWomb @DrEmmaCrosbie Vanitha Sivalingam neil ryan Eleanor Jones @MFT_SMH !
Pedro T Ramirez Arthur_HC_Hsu Aarthi S Jayraj Andreina Fernandes Ane Gerda Z Eriksson MD PhD IGCS ESGO European Network of Young Gynae Oncologists OncoAlert IJGC Fellows SoMe4GynOnc 💡Highlights
❇️ In #EndometrialCarcinoma patients, the rate of SLN mapping failure range from 20% to 25%
❇️Pooled data assessing predictive factors of SLN mapping failure in EC patients undergoing SLN biopsy through the cervical injection of indocyanine green (ICG) are lacking
Many congratulations to my friend and colleague Karen J Bai on her recent publication “Keratin 17 is a negative prognostic biomarker in high-grade #endometrialcarcinoma ”!
sciencedirect.com/science/articl…
ScienceDirect Stony Brook Pathology